MedTrace Logo

Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia

NCT00109356 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2007-05-07

No results posted yet for this study

Summary

The purpose of this study is to find answers to the following questions:

* What is the largest dose of AQ4N that can be given safely one time every three weeks for 24 weeks?
* What are the side effects of AQ4N when given according to this schedule?
* How much AQ4N is in the blood at certain times after administration and how does the body get rid of the drug?
* Will AQ4N help treat lymphoid cancer?

Conditions

Interventions

DRUG

AQ4N (Chemotherapy)

Sponsors & Collaborators

  • Novacea

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00109356 on ClinicalTrials.gov